Cell Induction and Regulation Field, Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan.
Tissue Eng Part A. 2021 Nov;27(21-22):1355-1367. doi: 10.1089/ten.TEA.2020.0346. Epub 2021 Aug 16.
Although bone has an innate capacity for repair, clinical situations such as comminuted fracture, open fracture, or the surgical resection of bone tumors produce critical-sized bone defects that exceed the capacity and require external intervention. Initiating endochondral ossification (EO) by the implantation of a cartilaginous template into the bone defect is a relatively new approach to cure critical-sized bone defects. The combination of chondrogenically primed mesenchymal stromal/stem cells and artificial scaffolds has been the most extensively studied approach for inducing endochondral bone formation in bone defects. In this study, we prepared cartilage (human-induced pluripotent stem [hiPS]-Cart) from hiPS cells (hiPSCs) in a scaffoldless manner and implanted hiPS-Cart into 3.5 mm large defects created in the femurs of immunodeficient mice to examine the repair capacity. For the control, nothing was implanted into the defects. The implantation of hiPS-Cart significantly induced more new bone in the defect compared with the control. Culture periods for the chondrogenic differentiation of hiPSCs significantly affected the speed of bone induction, with less time resulting in faster bone formation. Histological analysis revealed that hiPS-Cart induced new bone formation in a manner resembling EO of the secondary ossification center, with the cartilage canal, which extended from the periphery to the center of hiPS-Cart, initially forming in unmineralized cartilage, followed by chondrocyte hypertrophy at the center. In the newly formed bone, the majority of osteocytes, osteoblasts, and adipocytes expressed human nuclear antigen (HNA), suggesting that these types of cells mainly derived from the perichondrium of hiPS-Cart. Osteoclasts and blood vessel cells did not express HNA and thus were mouse. Finally, integration between the newly formed bone and mouse femur was attained substantially. Although hiPS-Cart induced new bone that filled bone defects, the newly formed bone, which is a hybrid of human and mouse, had not remodeled to mature bone within the observation period of this study (28 weeks). Impact statement Although bone has an innate capacity for repair, critical-sized bone defects that exceed the capacity require external intervention. We prepared cartilage (human-induced pluripotent stem [hiPS]-Cart) from hiPS cells (hiPSCs) in a scaffoldless manner and examined whether implantation of hiPS-Cart heals critical-sized defects created in the femurs of immunodeficient mice. The implantation of hiPS-Cart induced new bone in the defect in a manner resembling endochondral bone formation of the secondary ossification center. Although hiPS-Cart induced new bone that filled bone defects, the newly formed bone, which is a hybrid of human and mouse, had not remodeled to mature bone within the observation period of this study (28 weeks).
尽管骨骼具有内在的修复能力,但临床情况下,如粉碎性骨折、开放性骨折或骨肿瘤的手术切除会产生超出其能力范围的临界尺寸骨缺损,需要外部干预。通过将软骨模板植入骨缺损中启动骺软骨内成骨(endochondral ossification,EO)是一种治疗临界尺寸骨缺损的新方法。将经过软骨诱导的间充质基质/干细胞与人工支架相结合,是诱导骨缺损内骺软骨内成骨的最广泛研究方法。在这项研究中,我们以无支架的方式从人诱导多能干细胞(human-induced pluripotent stem,hiPS)中制备软骨(human-induced pluripotent stem [hiPS]-Cart),并将 hiPS-Cart 植入免疫缺陷小鼠股骨中的 3.5mm 大缺损中,以检测其修复能力。作为对照,缺损中未植入任何物质。与对照组相比,hiPS-Cart 的植入显著诱导了更多的新骨形成。hiPSCs 软骨分化的培养时间显著影响了骨诱导的速度,较短的时间导致更快的骨形成。组织学分析表明,hiPS-Cart 以类似于次级骨化中心 EO 的方式诱导新骨形成,软骨管从 hiPS-Cart 的外围延伸到中心,最初在未矿化的软骨中形成,随后在中心处软骨细胞肥大。在新形成的骨中,大多数成骨细胞、成骨细胞和脂肪细胞表达人核抗原(human nuclear antigen,HNA),提示这些类型的细胞主要来源于 hiPS-Cart 的软骨膜。破骨细胞和血管细胞不表达 HNA,因此为鼠源性。最后,新形成的骨与小鼠股骨之间实现了实质性的整合。尽管 hiPS-Cart 诱导了填充骨缺损的新骨,但在本研究的观察期(28 周)内,新形成的骨,即人-鼠混合骨,尚未重塑为成熟骨。